Navigation Links
Although Remicade and Humira Are Being Increasingly Prescribed for Crohn's Disease and Ulcerative Colitis, Insurers Are Subjecting Both Drugs to Multiple Cost-Control Strategies
Date:3/4/2008

Nearly One-Third of Surveyed Managed Care Organizations Levy Coinsurance Charges and Other Protocols on Remicade and Humira, According to a New

Report from Decision Resources

WALTHAM, Mass., March 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although gastroenterologists are increasingly prescribing Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade and Abbott/Eisai's Humira for the treatment of Crohn's disease and ulcerative colitis, a high proportion of managed care organizations (MCOs) subject both drugs to multiple cost-control strategies to keep costs down and limit the use of the two biologic therapies.

The new Physician & Payer Forum primary market research report entitled The Emergence of New Biologic Treatment Options for Crohn's Disease and Ulcerative Colitis: Physician and Payer Attitudes includes forecasts on the future of biological therapy in the treatment of Crohn's disease and ulcerative colitis, based on the views of prescribers and MCO pharmacy directors. According to the report, nearly one-third of the 20 MCOs surveyed levy coinsurance charges on Remicade and Humira and most plans require prior authorization for each drug. More than half of the plans that cover both drugs also employ step-therapy protocols. The report also finds that six of the 20 MCOs surveyed plan to extend their step therapy requirements during 2008 for Remicade, and five of 19 MCOs will do the same for Humira.

"Despite prior authorization and step therapy protocols that MCOs have put into place, both Remicade and Humira are being increasingly prescribed to patients with Crohn's disease," said Cindy Mundy, Ph.D. director at Decision Resources. "Humira, which was approved for Crohn's disease in January, 2007, is rapidly gaining ground on Remicade in terms of physician perceptions of key measures. We also found that approximately half of surveyed gastroenterologists consider the two drugs to be equal in treating Crohn's disease."

The Emergence of New Biologic Treatment Options for Crohn's Disease and Ulcerative Colitis: Physician and Payer Attitudes is based on a U.S. survey of 101 gastroenterologists and 20 managed care organization pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Physician & Payer Forum

Physician & Payer Forum is a primary research service from Decision Resources that offers access to high volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
2. Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
3. Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab)
4. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
5. Video: YMCAs Commit to Helping Americans Keep Their New Years Resolutions in Support of Health and Well-Being
6. K-State Trauma Researcher Says Being Prepared, Taking Action Are Vital in Preventing Tragedies Like the One at NIU
7. French paradox redux? US vs. French on being full
8. Select Comfort Creates Sleep Number Quality of Life Advisory Board to Improve Lives, Enhance Well-Being
9. Smart Home Cleaning: New Web Site Educates Consumers on Looking Clean Versus Being Clean
10. UM/Sylvester Offers Community the Gift of Well Being
11. Consumers Being Misled Over Bioavailabity of Resveratrol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Restoration, has recently contributed a medical article to the newly revamped Cosmetic ... Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an ... Puerto Rico , where the company ... Following a comprehensive onsite assessment, ... damage, temporary loss of power and minimal water damage ... operations have resumed, and the company expects to return ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
Breaking Medicine Technology: